R
Robert Kohberger
Researcher at Pfizer
Publications - 24
Citations - 7193
Robert Kohberger is an academic researcher from Pfizer. The author has contributed to research in topics: Conjugate vaccine & Pneumococcal conjugate vaccine. The author has an hindex of 19, co-authored 24 publications receiving 7011 citations. Previous affiliations of Robert Kohberger include University of Pennsylvania & York University.
Papers
More filters
Journal ArticleDOI
Design of a group-randomized Streptococcus pneumoniae vaccine trial.
Lawrence H. Moulton,Katherine L. O'Brien,Katherine L. O'Brien,Robert Kohberger,Ih Chang,Raymond Reid,Robert Weatherholtz,Jill G. Hackell,George R. Siber,Mathuram Santosham,Mathuram Santosham +10 more
TL;DR: A group-randomized, double-masked, phase III trial of a Streptococcus pneumoniae conjugate vaccine is being conducted in American Indian populations in the southwestern United States, the first such trial designed to lead to licensure of a drug or biologic in the United States.
Journal ArticleDOI
Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia
Mark Saaka,Brown J. Okoko,Robert Kohberger,Shabbar Jaffar,Godwin Enwere,Ekow Biney,Claire Oluwalana,Adeola Vaughan,Syed M. A. Zaman,L. Asthon,David Goldblatt,Brian Greenwood,Felicity T. Cutts,Felicity T. Cutts,Richard A. Adegbola +14 more
TL;DR: The PCV-9 studied was immunogenic in a Gambian population where it was also found to be efficacious and previously unpublished data on serotype-specific clinical vaccine efficacy from the main trial is reported.
Journal ArticleDOI
Predictors of Pneumococcal Conjugate Vaccine Immunogenicity among Infants and Toddlers in an American Indian PnCRM7 Efficacy Trial
Katherine L. O'Brien,Jennifer C. Moïsi,Lawrence H. Moulton,Dace V. Madore,Angelia A. Eick,Raymond Reid,Robert Weatherholtz,Eugene V. Millar,Diana Hu,Jill G. Hackell,Robert Kohberger,George R. Siber,Mathuram Santosham +12 more
TL;DR: Three-dose and 2-dose regimens for those 7-11 and 12-23 months of age, respectively, were highly immunogenic and increased maternal antibody concentrations were associated with reduced responses to dose 1 and 3 but not to dose 4 of PnCRM7.
Journal ArticleDOI
Prediction of pertussis vaccine efficacy using a correlates of protection model.
TL;DR: The model is used to predict efficacy from two recent immunogenicity trials comparing a 5-component acellular pertussis pentavalent combination vaccine with separate administration of its vaccine components and predicted similar protective efficacy rates.
Journal ArticleDOI
Economic burden of acute lower respiratory tract infection in South African children
Anushua Sinha,Soyeon Kim,Gary Ginsberg,Heather Franklin,Robert Kohberger,David R. Strutton,Shabir A. Madhi,Ulla K. Griffiths,Keith P. Klugman +8 more
TL;DR: ALRTI treatment cost the public health system an estimated US$28,975,000 while an additional US$539,000 of costs were borne by families and the South African public health-care system.